TLSI FY2026 EPS Estimate Lifted by Cantor Fitzgerald

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Analysts at Cantor Fitzgerald boosted their FY2026 EPS estimates for shares of TriSalus Life Sciences in a research report issued on Monday, November 17th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will earn ($0.10) per share for the year, up from their prior estimate of ($0.13). The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.79). The business had revenue of $11.57 million for the quarter, compared to analysts’ expectations of $11.76 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS.

A number of other equities analysts have also weighed in on the company. Wall Street Zen lowered TriSalus Life Sciences from a “hold” rating to a “sell” rating in a research note on Sunday, September 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of TriSalus Life Sciences in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.50.

TriSalus Life Sciences Stock Performance

Shares of TLSI stock opened at $4.60 on Wednesday. The company has a market capitalization of $229.40 million, a PE ratio of -2.28 and a beta of 0.47. TriSalus Life Sciences has a 52-week low of $3.42 and a 52-week high of $5.88. The business’s fifty day moving average is $4.69 and its 200 day moving average is $4.87.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of TLSI. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of TriSalus Life Sciences during the 2nd quarter valued at about $29,000. JPMorgan Chase & Co. grew its position in TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after acquiring an additional 7,519 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in TriSalus Life Sciences during the second quarter valued at approximately $47,000. Charles Schwab Investment Management Inc. bought a new stake in shares of TriSalus Life Sciences in the 1st quarter worth approximately $55,000. Finally, Sequoia Financial Advisors LLC purchased a new position in shares of TriSalus Life Sciences in the third quarter worth about $90,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.